NASDAQ · ALVO
Healthcare · Drug Manufacturers - Specialty & Generic
$5.02
Up+$0.08 (+1.59%)
Updated Sep 16, 2026, 10:18 PM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
ALVO closed at $5.02 after 20 trading sessions, up 27.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $5.05 | $5.07 | $4.90 | $5.02 | 610.03K |
| Sep 14, 2026 | $5.225 | $5.26 | $5.035 | $5.05 | 674.19K |
| Sep 11, 2026 | $5.28 | $5.39 | $5.26 | $5.29 | 667.87K |
| Sep 10, 2026 | $5.21 | $5.34 | $5.14 | $5.24 | 540.86K |
| Sep 9, 2026 | $5.15 | $5.24 | $5.06 | $5.21 | 572.36K |
| Sep 8, 2026 | $5.26 | $5.32 | $5.142 | $5.19 | 632.64K |
| Sep 4, 2026 | $5.31 | $5.40 | $5.205 | $5.32 | 535.4K |
| Sep 3, 2026 | $5.37 | $5.47 | $5.275 | $5.38 | 673.7K |
| Sep 2, 2026 | $5.24 | $5.415 | $5.171 | $5.34 | 700.3K |
| Sep 1, 2026 | $5.08 | $5.265 | $4.98 | $5.24 | 1.03M |
| Aug 31, 2026 | $5.00 | $5.265 | $4.98 | $5.19 | 1.25M |
| Aug 28, 2026 | $4.84 | $5.00 | $4.82 | $4.95 | 878.46K |
| Aug 27, 2026 | $4.88 | $4.9792 | $4.785 | $4.88 | 967.69K |
| Aug 26, 2026 | $4.98 | $4.99 | $4.782 | $4.91 | 890.18K |
| Aug 25, 2026 | $5.24 | $5.39 | $5.015 | $5.05 | 1.77M |
| Aug 24, 2026 | $4.79 | $5.359 | $4.715 | $5.25 | 3.18M |
| Aug 21, 2026 | $4.32 | $4.595 | $4.32 | $4.43 | 2.27M |
| Aug 20, 2026 | $3.89 | $4.37 | $3.75 | $4.27 | 1.37M |
| Aug 19, 2026 | $4.00 | $4.08 | $3.94 | $3.99 | 546.9K |
| Aug 18, 2026 | $3.92 | $4.00 | $3.83 | $3.95 | 675.58K |
The latest Smart Investors Daily articles mentioning ALVO.
ALVO research
Company profile and research snapshot.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | Barclays | Overweight | — |
| Aug 24, 2026 | B of A Securities | Buy | — |
| Aug 14, 2026 | Evercore ISI Group | Outperform | — |
| Mar 24, 2026 | UBS | Buy | — |
| Mar 24, 2026 | Barclays | Underweight | — |
Generated Sep 16, 2026, 9:02 PM
Alvotech shares gained 1.59% today as the biosimilar developer presented at the Morgan Stanley 24th Annual Global Healthcare Conference, providing investors with an update on the company's strategic direction and pipeline. The modest positive movement suggests cautious optimism from the market regarding management's presentation, though the neutral sentiment from coverage indicates investors are still digesting the messaging.
Bottom line: Alvotech's modest 1.59% gain reflects a neutral market reception to routine investor relations activity at the Morgan Stanley conference, rather than any significant fundamental catalyst or announcement. Investors should focus on pipeline progression, regulatory approvals, and commercial execution metrics rather than conference participation alone, while remaining cognizant of structural headwinds in the biosimilar market.
SeekingAlpha · Sep 15, 2026
Alvotech (ALVO) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 12:20 PM EDTCompany ParticipantsBalaji Prasad - Chief Strategy...
Yahoo · Aug 24, 2026
Alvotech (NASDAQ:ALVO) extended its winning streak to a 5th consecutive day on Monday, jumping 18.51 percent to finish at $5.25 apiece, after the Bank of America (BofA) raised its price target for the company. In its recent coverage, BofA initiated a buy recommendation on Alvotech shares with a price target of $7, amid the closure […]
Yahoo · Aug 24, 2026
Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.
Benzinga · Aug 24, 2026
B of A Securities analyst Jason Gerberry initiates coverage on Alvotech (NASDAQ:ALVO) with a Buy rating and announces Price Target of $7.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALVO.
